Please join us for a informative educational program:
Minimal Residual Disease (MRD) Assessment in the Management of Lymphoid Malignancies
This Minimal Residual Disease (MRD) webinar will address recent data supporting MRD assessment as a prognostic marker, provide evidence to support the increased role of MRD as a response assessment tool & the impact of MRD in novel therapies in clinical practice, and real world utilization of MRD. A review of MRD testing methodologies will also be covered.

Following this presentation attendees will be able to:

• Describe MRD and the prognostic value in lymphoid malignancies
• Describe different MRD assessment technologies
• Understand clinical data supporting the use of MRD

Target Audience:  Federal Health Care Providers, Hematologists, Lab personnel, Anyone interested in Management of Lymphoid Malignancies
Date: June 17, 2021
Time:   1-2 pm ET
Presenter: Allison Jacob, MSc, Medical Director, Med Affairs and Clinical Development at Adaptive Biotechnologies

 

This webinar is sponsored by: